A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Age ≥ 18 years
Histologically or cytologically confirmed locally advanced or metastatic solid tumor and PDAC with RAS mutation or KRAS amplification
At least one measurable lesion according to RECIST v1.1
ECOG performance status 0 or 1
Other active malignancy within 3 years
Symptomatic brain metastases, leptomeningeal disease, spinal cord compression, or primary brain tumor
History of active clinically significant cardiovascular dysfunction
For participants with known concomitant second oncodriver for PDAC or for solid tumors.